AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26307030 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 1256
Study 24520101 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma procalcitonin levels
Number of subjects: 50
Study 24520101 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 50
Study 24520101 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin levels in idiopathic scoliosis patients
Number of subjects: 50
Study 24520101 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin levels in neuromuscular scoliosis patients
Number of subjects: 50
Study 22313792 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin plus oxybutynin (5 mg)
Number of subjects: 206
Study 22313792 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin plus placebo
Number of subjects: 206
Study 18834819 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60
Study 18834819 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 60
Study 17767476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg/day) + Proton Pump Inhibitor (PPI)
Number of subjects: 62
Study 17767476 — intervention group
Group type: COMPARATOR
Intervention: Proton Pump Inhibitor (PPI) alone
Number of subjects: 62
Study 14695387 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1 mmol/kg)
Number of subjects: 27
Study 14695387 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.1 mmol/kg)
Number of subjects: 27
Study 12231497 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 48
Study 12231497 — intervention group
Group type: COMPARATOR
Intervention: Mandibular Repositioning Splint (MRS)
Number of subjects: 48
Study 12231497 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP in patients with mild SAHS (AHI < 15, n = 18)
Number of subjects: 48
Study 9682109 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ alignment group
Number of subjects: 71
Study 9682109 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine refraction)
Number of subjects: 71
Study 8131704 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 31
Study 8131704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8131704 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (22 healthy volunteers)
Number of subjects: 31
Study 3419597 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (suprathreshold rates)
Number of subjects: 8
Study 3419597 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (threshold rates)
Number of subjects: 8
Study 3419597 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (subthreshold rates)
Number of subjects: 8
Study 3419597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31077093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture plus Case‐based Learning (CBL)
Number of subjects: 140
Study 31077093 — intervention group
Group type: COMPARATOR
Intervention: Lecture only (Control group)
Number of subjects: 140
Study 31077093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture plus CBL
Number of subjects: 140
Study 31118278 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge pencil point spinal needles
Number of subjects: 140
Study 31118278 — intervention group
Group type: COMPARATOR
Intervention: 27-gauge pencil point spinal needles
Number of subjects: 140
Study 28869006 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (400 mg for first 4 weeks, titrated up to 800 mg for remaining 8 weeks)
Number of subjects: 68
Study 28869006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two matching capsules for first 4 weeks, titrated to four matching capsules for remaining 8 weeks)
Number of subjects: 68
Study 24816997 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 20
Study 24816997 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 20
Study 24816997 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring in multiple daily insulin patients
Number of subjects: 20
Study 24050845 — intervention group
Group type: EXPERIMENTAL
Intervention: Down syndrome (DS) group
Number of subjects: 48
Study 24050845 — intervention group
Group type: COMPARATOR
Intervention: NDS group
Number of subjects: 48
Study 17144387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 60
Study 17144387 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 60
Study 12680744 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyclidine (15 mg, oral)
Number of subjects: 0
Study 12680744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10100062 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion in hypertensive patients
Number of subjects: 85
Study 10100062 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-glucose load plasma insulin in hypertensive patients with microalbuminuria (n = 14)
Number of subjects: 85
Study 10100062 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP quartile analysis
Number of subjects: 85
Study 10100062 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis including plasma insulin, systolic and diastolic BP, plasma glucose, triglycerides, and body mass index
Number of subjects: 85
Study 10100062 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia in hypertensive and normotensive atherosclerotic patients
Number of subjects: 85
Study 8669993 — intervention group
Group type: COMPARATOR
Intervention: Knee immobilization (I)
Number of subjects: 10
Study 8669993 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-inch shoe-lift (I1/2")
Number of subjects: 10
Study 8669993 — intervention group
Group type: EXPERIMENTAL
Intervention: One-inch shoe-lift (I1")
Number of subjects: 10
Study 1802019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 1.5 mg/m2/day
Number of subjects: 16
Study 1802019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 1.0 mg/m2/day
Number of subjects: 16
Study 1802019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 1.25 mg/m2/day
Number of subjects: 16
Study 6305183 — intervention group
Group type: COMPARATOR
Intervention: Soya pulp A (39% dietary fiber)
Number of subjects: 6
Study 6305183 — intervention group
Group type: COMPARATOR
Intervention: Purified soya fiber B (79% dietary fiber)
Number of subjects: 6
Study 31429205 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-385 (320/80 mg loading/maintenance)
Number of subjects: 43
Study 31429205 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-385 (various doses)
Number of subjects: 43
Study 29087256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone ownership and stability
Number of subjects: 121
Study 29087256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone instability
Number of subjects: 121
Study 25595923 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant bilateral radiofrequency pulmonary vein ablation (group A)
Number of subjects: 175
Study 25595923 — intervention group
Group type: COMPARATOR
Intervention: CABG alone (group B)
Number of subjects: 175
Study 23794569 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus aerobic exercise
Number of subjects: 104
Study 23794569 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study 21729277 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex oral health care (OHC) intervention
Number of subjects: 0
Study 19656355 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (anesthetic)
Number of subjects: 28
Study 19656355 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 28
Study 17484298 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted zero-inflated Poisson model (W-ZIP)
Number of subjects: 0
Study 17484298 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression (LR)
Number of subjects: 0
Study 17484298 — intervention group
Group type: COMPARATOR
Intervention: Survival analysis
Number of subjects: 0
Study 15612857 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness therapy (FT)
Number of subjects: 14
Study 15612857 — intervention group
Group type: COMPARATOR
Intervention: Alternative individual treatment based on routine drug and alcohol therapy topics
Number of subjects: 14
Study 11726414 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 56
Study 11726414 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 56
Study 9394699 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g cooked field bean flour/d (groups B and C)
Number of subjects: 40
Study 9394699 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g raw field bean flour/d (group D)
Number of subjects: 40
Study 9394699 — intervention group
Group type: COMPARATOR
Intervention: 90 g control flour/d (group A)
Number of subjects: 40
Study 7696825 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (time-release preparation)
Number of subjects: 49
Study 7696825 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (standard tablet preparation)
Number of subjects: 49
Study 7696825 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of pamidronate and use of antacid medication
Number of subjects: 49
Study 2954077 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide 600 mg/m2 + 5-fluorouracil 750 mg/m2 + adriamycin 45 mg/m2)
Number of subjects: 142
Study 2954077 — intervention group
Group type: EXPERIMENTAL
Intervention: CNF (cyclophosphamide 600 mg/m2 + 5-fluorouracil 750 mg/m2 + mitoxantrone 13 mg/m2)
Number of subjects: 142
Study 2954077 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 142
Study 2954077 — intervention group
Group type: EXPERIMENTAL
Intervention: CNF
Number of subjects: 142
Study 31789623 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-acquired pressure injury (HAPI)
Number of subjects: 415
Study 30109375 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo manipulation consisting of verbal suggestion and conditioning
Number of subjects: 0
Study 30109375 — intervention group
Group type: COMPARATOR
Intervention: Control group informed about the real nature of the cream
Number of subjects: 0
Study 28393781 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan at 0.1 μg/kg/min
Number of subjects: 80
Study 28393781 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine at 5 μg/kg/min
Number of subjects: 80
Study 26237195 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncircular chainring (NCC)
Number of subjects: 11
Study 26237195 — intervention group
Group type: COMPARATOR
Intervention: Conventional circular chainring (CC)
Number of subjects: 11
Study 25087294 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil/exercise training group (T/E group, n = 10)
Number of subjects: 20
Study 25087294 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil group (T group, n = 10)
Number of subjects: 20
Study 21167363 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly training for 4 weeks
Number of subjects: 24
Study 21167363 — intervention group
Group type: COMPARATOR
Intervention: Monthly training for 4 months
Number of subjects: 24
Study 18633699 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PAD session
Number of subjects: 462
Study 18633699 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 462
Study 17152553 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoscopic photography
Number of subjects: 100
Study 17152553 — intervention group
Group type: COMPARATOR
Intervention: Stereoscopic photography
Number of subjects: 100
Study 12860539 — intervention group
Group type: EXPERIMENTAL
Intervention: semitendinosus tendon autograft
Number of subjects: 90
Study 12860539 — intervention group
Group type: EXPERIMENTAL
Intervention: semitendinosus and gracilis tendon autograft
Number of subjects: 90
Study 10889125 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lowering of LDL cholesterol levels to <100 mg/dL
Number of subjects: 1351
Study 10889125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose anticoagulation
Number of subjects: 1351
Study 10889125 — intervention group
Group type: COMPARATOR
Intervention: Moderate reduction of LDL cholesterol to 132-136 mg/dL
Number of subjects: 1351
Study 10889125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1351
Study 8957147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 86
Study 8957147 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 86
Study 1568366 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (d-F) 15 mg, two capsules daily
Number of subjects: 36
Study 1568366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) 2 capsules daily
Number of subjects: 36
Study 2864791 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal desensitization (ID)
Number of subjects: 20
Study 2864791 — intervention group
Group type: COMPARATOR
Intervention: Covert sensitization (CS)
Number of subjects: 20
Study 30763041 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive tool providing cesarean delivery rate data for 10 closest hospitals
Number of subjects: 18293
Study 30763041 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interactive tool)
Number of subjects: 18293
Study 30763041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (with interactive tool)
Number of subjects: 18293
Study 30053891 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term abdominal drains (LTAD) for 12 weeks
Number of subjects: 48
Study 30053891 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care (large volume paracentesis [LVP]) for 12 weeks
Number of subjects: 48
Study 27397441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 mcg/kg loading dose over 15 min, followed by 0.5 mcg/kg/h maintenance infusion)
Number of subjects: 60
Study 27397441 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study 23481373 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist Empathy Scale (TES)
Number of subjects: 315
Study 21861683 — intervention group
Group type: EXPERIMENTAL
Intervention: Long display durations (displays visible until response onset)
Number of subjects: 0
Study 21861683 — intervention group
Group type: EXPERIMENTAL
Intervention: Short display durations (displays visible for only 200 msec)
Number of subjects: 0
Study 20483671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for dysmenorrhea
Number of subjects: 0
Study 20483671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for menopause
Number of subjects: 0
Study 20483671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for PMS
Number of subjects: 0
Study 20483671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for PCOS
Number of subjects: 0
Study 20483671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for other menstrual related symptoms
Number of subjects: 0
Study 17073850 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with a plasmatic target concentration of 4 mg/l (group P; n= 26)
Number of subjects: 52
Study 17073850 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 4% with tidal volume ventilation (group S; n= 26)
Number of subjects: 52
Study 16338276 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir (600 mg) with water (control)
Number of subjects: 20
Study 16338276 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (600 mg) with Seville orange juice
Number of subjects: 20
Study 16338276 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 expressors (6 subjects)
Number of subjects: 20
Study 16338276 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 nonexpressors (14 subjects)
Number of subjects: 20
Study 11889302 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV‐PAV
Number of subjects: 12
Study 11889302 — intervention group
Group type: COMPARATOR
Intervention: NIV‐PSV
Number of subjects: 12
Study 10716008 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education brochure (ZDV therapy)
Number of subjects: 653
Study 7720343 — intervention group
Group type: EXPERIMENTAL
Intervention: Random urine sample with threshold albumin-creatinine ratio of > or = 3.0 mg/mmol
Number of subjects: 50
Study 7720343 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight urine collection with threshold values of 2.5 mg/mmol for men and 4.5 mg/mmol for women
Number of subjects: 50
Study 7720343 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot albumin-creatinine ratio
Number of subjects: 50
Study 2119417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg b.i.d. for 6 weeks, then 20 mg b.i.d. for 6 weeks)
Number of subjects: 120
Study 2119417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g d-1 or highest tolerable dose)
Number of subjects: 120
Study 2119417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 6783416 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (45 min/day, 3 times/week for 12 weeks at 80% VO2 max)
Number of subjects: 24
Study 6783416 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 24
Study 6783416 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 13, age 39 +/- 5.0)
Number of subjects: 24
Study 29373395 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rDTMS treatment
Number of subjects: 48
Study 29373395 — intervention group
Group type: COMPARATOR
Intervention: Sham rDTMS treatment
Number of subjects: 48
Study 28318388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention with individualized nutrition plan (1.0‐1.5 g/kg) and dietary advice
Number of subjects: 55
Study 28318388 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional management (control group)
Number of subjects: 55
Study 28318388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 55
Study 25753895 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA (butter)
Number of subjects: 0
Study 25753895 — intervention group
Group type: COMPARATOR
Intervention: n-6PUFA (vegetable oil)
Number of subjects: 0
Study 23817692 — intervention group
Group type: EXPERIMENTAL
Intervention: SOA combined with tegafur-uracil (group B)
Number of subjects: 52
Study 23817692 — intervention group
Group type: COMPARATOR
Intervention: SOA alone (group A)
Number of subjects: 52
Study 21114350 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem manipulation and death cognition manipulation
Number of subjects: 0
Study 21114350 — intervention group
Group type: COMPARATOR
Intervention: Death cognition manipulation
Number of subjects: 0
Study 18249333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotline group (warmed intravenous fluids to 41 degrees C)
Number of subjects: 40
Study 18249333 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized institutional practice without warmed intravenous fluids)
Number of subjects: 40
Study 18249333 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Hotline and Control)
Number of subjects: 40
Study 16340591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine gel (50 mg/mL), applied topically 10 minutes before capsaicin injection
Number of subjects: 9
Study 16340591 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 9
Study 11786767 — intervention group
Group type: EXPERIMENTAL
Intervention: Open hemorrhoidectomy (Group A, n = 40)
Number of subjects: 80
Study 11786767 — intervention group
Group type: COMPARATOR
Intervention: Closed hemorrhoidectomy (Group B, n = 40)
Number of subjects: 80
Study 9834769 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 344
Study 9834769 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin
Number of subjects: 344
Study 9834769 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 344
Study 9834769 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 344
Study 8087913 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 0
Study 8087913 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (halothane or isoflurane)
Number of subjects: 0
Study 2681348 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (hGH) alone
Number of subjects: 0
Study 2681348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with hGH and oxandrolone
Number of subjects: 0
Study 2681348 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study 15741980 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation care for SCI patients in 148 units across metropolitan France
Number of subjects: 934
Study 495549 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet
Number of subjects: 12
Study 495549 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber diet
Number of subjects: 12
Study 29704437 — intervention group
Group type: EXPERIMENTAL
Intervention: SQS + OMM
Number of subjects: 116
Study 29704437 — intervention group
Group type: COMPARATOR
Intervention: OMM
Number of subjects: 116
Study 27655325 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusion of 1 mL/Kg of crystalloid over 5 minutes
Number of subjects: 80
Study 27655325 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusion of 4 mL/Kg of crystalloid over 5 minutes
Number of subjects: 80
Study 27655325 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL/Kg of crystalloid
Number of subjects: 80
Study 26588599 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless surgical protocol (n = 20 patients; 32 implants)
Number of subjects: 41
Study 26588599 — intervention group
Group type: COMPARATOR
Intervention: Flapped surgical protocol (n = 21 patients; 40 implants)
Number of subjects: 41
Study 26588599 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 41
Study 26588599 — intervention group
Group type: COMPARATOR
Intervention: Flap group
Number of subjects: 41
Study 26588599 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless group
Number of subjects: 41